A combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: a case report

INTRODUCTION: Chronic refractory immune thrombocytopenic purpura can be a challenging condition to treat. By definition, the standard first and second line treatments have failed in these patients and modalities such as thrombopoiesis-stimulating agents and more intensive immunosuppressive drugs are...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinayek, Namita, Sharma, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917596/
https://www.ncbi.nlm.nih.gov/pubmed/24428822
http://dx.doi.org/10.1186/1752-1947-8-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917596/
https://www.ncbi.nlm.nih.gov/pubmed/24428822
http://dx.doi.org/10.1186/1752-1947-8-19

Ejemplares similares